This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Metachromatic leukodystrophy is a neurodegenerative condition with a variable rate of progression that warrants more systematic investigation. In their natural history study of 98 patients with metachromatic leukodystrophy, Dr. Kehrer et al. summarize the prominent symptoms and age of symptom onset according to various forms of the illnesses (late infantile, early juvenile, late juvenile, and adult). In younger persons (under age 6 years), motor manifestations with or without cognitive impairment were common, whereas in late juvenile and adult forms, cognitive symptoms became increasingly common. Patients with earlier disease onset experienced more rapid progression. Dr. Michell-Robinson and Lépine hypothesize that arylsulfatase A activity (the defective enzyme in metachromatic leukodystrophy) and therefore buildup of toxic sulfatide levels might be related to the severity or progression of the illness. Because some older patients may also experience rapid declines, the investigators do not believe sulfatide toxicity to be the primary mediator of disease severity. They also emphasize the importance of motor system involvement as a driver of neurologic deterioration. Although there is much more to understand about this condition, it is clear now that motor symptom manifestations typically precede rapid disease progression.
Metachromatic leukodystrophy is a neurodegenerative condition with a variable rate of progression that warrants more systematic investigation. In their natural history study of 98 patients with metachromatic leukodystrophy, Dr. Kehrer et al. summarize the prominent symptoms and age of symptom onset according to various forms of the illnesses (late infantile, early juvenile, late juvenile, and adult). In younger persons (under age 6 years), motor manifestations with or without cognitive impairment were common, whereas in late juvenile and adult forms, cognitive symptoms became increasingly common. Patients with earlier disease onset experienced more rapid progression. Dr. Michell-Robinson and Lépine hypothesize that arylsulfatase A activity (the defective enzyme in metachromatic leukodystrophy) and therefore buildup of toxic sulfatide levels might be related to the severity or progression of the illness. Because some older patients may also experience rapid declines, the investigators do not believe sulfatide toxicity to be the primary mediator of disease severity. They also emphasize the importance of motor system involvement as a driver of neurologic deterioration. Although there is much more to understand about this condition, it is clear now that motor symptom manifestations typically precede rapid disease progression.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- © 2021 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.